GPC Biotech AG (Nasdaq: GPCB) 34.2% LOWER; Fails to win FDA panel backing for prostate cancer drug. FDA panel votes ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE